A novel mechanism of factor VIII protection by von Willebrand factor from activated protein C–catalyzed inactivation
Open Access
- 1 June 2002
- journal article
- Published by American Society of Hematology in Blood
- Vol. 99 (11) , 3993-3998
- https://doi.org/10.1182/blood.v99.11.3993
Abstract
The protective effect of von Willebrand factor (VWF) toward activated protein C (APC)–catalyzed inactivation of factor VIII (FVIII) has been attributed mainly to inhibition of FVIII binding to phospholipid. In the present study, we demonstrated that VWF-mediated FVIII protection from APC also results from direct inhibition of FVIII binding to APC. Inhibition of FVIII binding to anhydro-APC by VWF would be consistent with partial or complete overlap of the FVIII binding sites for APC and VWF. We examined, therefore, the inhibitory effects of 6 synthetic peptides spanning residues 1996 to 2028 around the previously localized APC binding region (FVIII residues 2009-2018). Peptide 2009 to 2018 inhibited FVIII binding to anhydro-APC by 83% (50% inhibition, 55 μM). Similarly, peptide 2013 to 2022 inhibited FVIII binding to VWF by 84% (50% inhibition, 25 μM). It was also found that peptides 2009 to 2018 and 2013 to 2022 optimally bound to anhydro-APC and VWF, respectively. A rabbit antipeptide IgG, raised against peptide 2009 to 2022, blocked the binding of both anhydro-APC and VWF to FVIII. This immunoglobulin G inhibited proteolytic cleavage of FVIII by APC. Our results indicate that the essential regions for the binding of APC and VWF to FVIII overlap and that the protective effect of VWF on APC-catalyzed FVIII inactivation includes competitive inhibition of APC binding to FVIII by VWF.Keywords
This publication has 21 references indexed in Scilit:
- The Light Chain of Factor VIII Comprises a Binding Site for Low Density Lipoprotein Receptor-related ProteinJournal of Biological Chemistry, 1999
- Inactivation of factor VIII by factor IXaBiochemistry, 1992
- Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy chain.Journal of Clinical Investigation, 1988
- Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activityBiochemistry, 1986
- Molecular cloning of a cDNA encoding human antihaemophilic factorNature, 1984
- Structure of human factor VIIINature, 1984
- Expression of active human factor VIII from recombinant DNA clonesNature, 1984
- [15] Preparation of site-specific anti-cytochrome c antibodies and their applicationPublished by Elsevier ,1981
- Human blood platelet adhesion to artery subendothelium is mediated by factor VIII–Von Willebrand factor bound to the subendotheliumNature, 1979
- Stabilization of Factor VIII in Plasma by the von Willebrand FactorJournal of Clinical Investigation, 1977